Anzeige
Erschienen in:
01.02.2009 | Original Article
Longitudinal assessment of cerebral 5-HT2A receptors in healthy elderly volunteers: an [18F]-altanserin PET study
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2009
Einloggen, um Zugang zu erhaltenAbstract
Purpose
The serotonin 2A (5-HT2A) receptor is of interest in several psychiatric and neurological diseases. In the present study we investigated the longitudinal stability of 5-HT2A receptors and the stability of the quantification procedure in the elderly in order to be able to study elderly patients with neuropsychiatric diseases on a longitudinal basis.
Methods
[18F]-Altanserin PET was used to quantify 5-HT2A receptors in 12 healthy elderly individuals at baseline and at 2 years in six volumes of interest. A bolus/infusion protocol was used to achieve the binding potential, BPP. The reproducibility as assessed in terms of variability and the reliability as assessed in terms of intraclass correlation coefficient (ICC) were used to compare inter- and intraobserver stability and to evaluate the effects of increasing complexity of partial volume (PV) corrections. We also compared the stability of our measurements over 2 years with the stability of data from an earlier study with 2-week test–retest measurements.
Results
BPP was unaltered at follow-up without the use of PV correction and when applying two-tissue PV correction, test–retest reproducibility was 12–15% and reliability 0.45–0.67 in the large bilateral regions such as the parietal, temporal, occipital and frontal cortices, while orbitofrontal and anterior cingulate cortical regions were less stable. The use of PV correction decreased the variability but also decreased the between-subject variation, thereby worsening the reliability.
Conclusion
In healthy elderly individuals, brain 5-HT2A receptor binding remains stable over 2 years, and acceptable reproducibility and reliability in larger regions and high intra- and interobserver stability allow the use of [18F]-altanserin in longitudinal studies of patients with neuropsychiatric disorders.